

Areas of Strategic Interest

ZIFTOMENIB
INTERVENTIONAL PROPOSALS
ACUTE MYELOID LEUKEMIA <ul style="list-style-type: none">• NPM1 MRD status and its role of informing treatment• Investigating Ziftomenib in difficult-to-treat or special populations of high unmet need (i.e. elderly, co-mutated, specific line of therapy or prior treatments)• Combinations with intermediate intensive chemotherapy (IC)• Combinations with other targeted therapies• Incorporating Ziftomenib into stem cell transplant, including pre- and post-transplant and/or post-induction regimens• In populations that may be dependent on HOX/MEIS gene signatures
OTHER LEUKEMIAS <ul style="list-style-type: none">• Ziftomenib use in other leukemias
PEDIATRICS

Kura is currently accepting proposals for Investigator Sponsored Studies and Collaborative Research for Ziftomenib in the United States (US).
